Evidence map›Paper›PMID 41817574›Full record

ArticleCancer research2026

PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer.

Zihan Xia, Felix De Vuyst, Sam Ernst, Ujjwal Suwal, Amélie Vander Cruyssen, Pekka Rappu, Jyrki Heino, Sándor Dedeyne, Wim Ceelen, Ligia Craciun and 3 more

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zihan Xia *Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0009-0001-1935-2183
Felix De Vuyst *Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0003-2364-7504
Sam ErnstLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0003-2210-8007
Ujjwal SuwalDepartment of Life Technologies and InFLAMES Flagship, University of Turku, Turku, Finland.ORCID 0000-0002-9389-2911
Amélie Vander CruyssenLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0001-8785-5834
Pekka RappuDepartment of Life Technologies and InFLAMES Flagship, University of Turku, Turku, Finland.ORCID 0000-0002-5068-2842
Jyrki HeinoDepartment of Life Technologies and InFLAMES Flagship, University of Turku, Turku, Finland.ORCID 0000-0003-2978-805X
Sándor DedeyneLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0002-0031-1306
Wim CeelenCancer Research Institute Ghent, Ghent, Belgium.ORCID 0000-0001-7692-4419
Ligia CraciunDivision CMP, Cerba Path, Brussels, Belgium.ORCID 0000-0001-6540-8232
Pieter DemetterDivision CMP, Cerba Path, Brussels, Belgium.ORCID 0000-0001-7981-4645
An HendrixLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0002-1883-8309
Olivier De WeverLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0002-5453-760X

Funding

Bijzonder Onderzoeksfonds UGent (BOF)China Scholarship Council (CSC) 202006160045Kom op tegen Kanker (Fight Cancer)Stichting Tegen Kanker (Fondation Contre le Cancer)
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAF) exhibit phenotypic heterogeneity with each functional state playing critical roles in tumor progression. Notably, subtypes like inflammatory CAFs (iCAF), characterized by increased chemokine/cytokine secretion, and myofibroblast-like CAFs (myCAF), characterized by enhanced extracellular matrix (ECM) deposition and increased actomyosin contractility, can undergo phenotypic switching in response to cues from the tumor microenvironment and therapeutic interventions. Elucidation of the signaling pathways associated with the diverse phenotypes could enable development of strategies to therapeutically reprogram CAFs. Through the analysis of single-cell RNA sequencing data from patients with colorectal cancer, we identified that the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways, among other pathways, are linked to the formation of myCAF and iCAF subtypes, respectively. Unbiased pharmacologic interference of 12 distinct signaling pathways using three-dimensional (3D) human colorectal cancer-derived CAF cultures, ex vivo patient-derived tumor fragments, and mouse models further revealed the significance of PI3K/mTOR and MAPK/ERK signaling in CAF plasticity and functional behavior. PI3K/mTOR inhibition drove iCAF formation through compensatory FGF2 release and FGFR1-JAK2-STAT3 activation, leading to chemokine/cytokine secretion that promoted tumor spheroid growth and neutrophil infiltration. Conversely, MEK inhibition induced a myCAF phenotype via interferon-dependent ROCK and JAK1 signaling, resulting in ECM production that enhanced tumor colony formation. In summary, these findings reveal a functional significance of PI3K/mTOR and MAPK/ERK signaling pathways in CAF plasticity and underscore how standard-of-care targeted therapies can directly influence CAF phenotypes in colorectal cancer. SIGNIFICANCE: The PI3K/mTOR and MAPK/ERK signaling pathways regulate the formation of CAF subtypes in colorectal cancer, providing insights into how fibroblasts adapt to cancer-targeted therapies and potential strategies to harness stromal plasticity.

Indexed as

Cancer-Associated FibroblastsColorectal NeoplasmsMAP Kinase Signaling SystemPhosphatidylinositol 3-KinasesAnimalsCell PlasticityHumansMicePhenotypeSignal TransductionTOR Serine-Threonine KinasesTumor MicroenvironmentMTOR protein, humanPhosphatidylinositol 3-KinasesTOR Serine-Threonine Kinases

Identifiers

PMID41817574
PMCPMC13266349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.